
## NUCLEAR MEDICINE IMAGING IN FUO

Christophe Van de Wiele, M.D., Ph.D. Department of Nuclear Medicine, University Hospital, Ghent, Belgium

### NUCLEAR MEDICINE IMAGING IN FUO

- Definitions and classifications
- Causes of FUO
- Diagnostic approach



Category of FUO	Definition	Common etiologies
Classic	Temperature >38.3°C (100.9°F) Duration of >3 weeks Evaluation of at least 3 outpatient visits or 3 days in hospital	Infection, malignancy, collagen vascular disease
Nosocomial	Temperature >38.3°C Patient hospitalized ≥24 hours but no fever or incubating on admission Evaluation of at least 3 days	Clostridium difficile enterocolitis, drug-induced, pulmonary embolism, septic thrombophlebitis, sinusitis
Immune deficient (neutropenic)	Temperature >38.3°C Neutrophil count ≤500 per mm³ Evaluation of at least 3 days	Opportunistic bacterial infections, aspergillosis, candidiasis, herpes virus
HIV-associated	Temperature >38.3°C Duration of >4 weeks for outpatients, >3 days for inpatients HIV infection confirmed	Cytomegalovirus, Mycobacterium avium-intracellulare complex, Pneumocystis carinii pneumonia, drug-induced,Kaposi's sarcoma, lymphoma
HIV = human immun	ocleficiency virus	


## **FUO : future definition**

- Illness > 3 weeks duration
- Temperature ≥ 38.3 °C or lower with laboratory signs of inflammation on ≥ 3 occasions
- Lack of diagnosis or reasonable hypothesis after a relevant diagnostic investigation
- Exclusion of nosocomial fevers and severe immunocompromise
- Bleeker-Rovers et al. FUO. Sem Nucl Med 2009; 39: 81-87

	FUO : DEFINITION
Table	1. Minimal Diagnostic Workup to Qualify as Fever of Unknown Origin
Comp	ehensive history
	al examination
Compl	ete blood cell count + differential
	ilm reviewed by hematopathologist
	e blood chemistry (including lactic dehydrogenase, bilirubin, and liver enzymes)
	sis and microscopy
	(×3) and urine cultures
	clear antibodies, rheumatoid factor
Cytom	n immunodeficiency virus antibody egalovirus IgM antibodies; heterophil antibody test (if consistent with mononucleosis-like Irome)
Q-feve	r serology (if exposure risk factors exist)
Chest	adiography
	tis serology (if abnormal liver enzyme test result)

### NUCLEAR MEDICINE IMAGING IN FUO

- Definitions and classifications
- Causes of FUO
- Diagnostic approach



#### TABLE 3 Agents Commonly Associated with Drug-Induced Fever

Allopurinol (Zyloprim) Captopril (Capoten) Cimetidine (Tagamet) Clofibrate (Atromid-S) Erythromycin Heparin Hydralazine (Apresoline) Hydrochlorothiazide (Esidrix) Isoniazid Meperidine (Demerol) Methyldopa (Aldomet) Nifedipine (Procardia) Nitrofurantoin (Furadantin) Penicillin Phenytoin (Dilantin) Procainamide (Pronestyl) Quinidine


Roth et al. Am Fam Physician: 2003; 68:2223-2238

### **CAUSES OF FUO: MOST FREQUENT**

- Endocarditis, TB, abdominal abcesses, EBV and CMV
- Lymphoma, leukemia
- Adult onset Still disease, SLE, PMR/giant cell arteritis, sarcoidosis
- M. Crohn, subacute thyroiditis, habitual hyperthermia (young woman, neurotic, months to years, low grade, fatigue, myalgia, ..), drug fever

### **CAUSES OF FUO: Spectrum def. factors**

- Time era of the study (diagnostic means)
- Geographic factors
- Patient age
- Duration of the fever
- Type of hospital




	Elderly(n=204)	Young(n=152)
Infection	72(35)	33(21)
-Tuberculosis	20(10)	4(3)
-Abscess	25(12)	6(4)
-Endocarditis	14(7)	2(1)
-Viral	1(0.05)	8(5)
Tumour	38(19)	8(5)
SID's	57(28)	27(17)



- Definitions and classifications
- Causes of FUO
- Diagnostic approach

## Diagnostic approach of FUO

- « pdc » = potentially diagnostic clues
  Look for them
- If no pdc's and/or directed examinations neg
  - Staged approach
  - Total body inflammation/inefction scan
  - Therapeutic trials
  - Wait and see strategy



## Diagnostic approach of FUO

- « pdc » = potentially diagnostic clues
  - Look for them
- If no pdc's and/or directed examinations neg
  - Staged approach
  - Total body inflammation/infection scan
  - Therapeutic trials
  - Wait and see strategy


### Total Body Inflammation/infection scan

- <sup>67</sup>Ga-scintigraphy
- Labeled leucocytes
- FDG PET

# 67Ga-scintigraphy in FUO

### Long time assumed « gold standard »,


- Pros'
  - acute and chronic inflammatory conditions
  - Some neoplasms
- Con's
  - Poor specificity
  - Duration of imaging, suboptimal decay
- Largest study: Knockaert et al. Clin Infect Dis 1994;18
  - N=145 pts (1980-1989)
  - Final diagnosis available in 68% (99pts)
  - 82 abnormal scans (57%), 42 of these were helpfull (49%)




### Fotal Body Inflammation/infection scan

- <sup>67</sup>Ga-scintigraphy
- Labeled leucocytes
- FDG PET

	Nb	Se	Spe.	Accuracy			
Syrjala et al.1987(JNM)	68	81%	90%	87%			
Schmidt et al. 1987(SJID)	32	?	100%	?			
McSweeneyet al. 1990(ClRad)	25	55%	79%	74%			
Kjaer et al. 2002(JNM)	31	75%	83%	-			
<sup>99m</sup> TC-antigranulocyte Ab scintigraphy							
	34	40%	90%				
Becker et al. 1993(EJNM)							






## FDG PET(-CT) IMAGING IN FUO

TABLE I.—Studies with FDG-PET in patients with classical FUO.

N.     IF (%)     ID (%)     NP (%)     MISC (%)     ND (%)       Meller et al. <sup>52</sup> p     20     40     25 (15)     10     15     10     55 (PPV; 92;       Blockmans et al. <sup>54</sup> p     58     18     29 (14)     10     9     34     41 (PPV:;       Lorenzen et al. <sup>53</sup> r     16     19     50 (18)     6     6     19     69 (PPV: 92;       Bleeker-Rovers et al. <sup>55</sup> r     35     17     11 (3)     17     9     46     37 (PPV: 87;       Bleeker-Rovers et al. <sup>56</sup> p     19     26     16 (5)     6     16     36     16 (PVY: 30;       Buysschaert et al. <sup>57</sup> r     74     9     5 (4)     16     19     51     26 (PPV: -;     12	Author	Design		Patients (n=292)					PET helpful (%)	
Blockmans <i>et al.</i> <sup>54</sup> p 58 18 29 (14) 10 9 34 41 (PPV:; Lorenzen <i>et al.</i> <sup>53</sup> r 16 19 50 (18) 6 6 19 69 (PPV: 92; Bleeker-Rovers <i>et al.</i> <sup>55</sup> r 35 17 11 (3) 17 9 46 37 (PPV: 87; Kjaer <i>et al.</i> <sup>56</sup> p 19 26 16 (5) 6 16 36 16 (PPV: 30; Buyschaert <i>et al.</i> <sup>57</sup> r 74 9 5 (4) 16 19 51 26 (PPV:; Bleeker-Rovers <i>et al.</i> <sup>58</sup> p 70 17 23 (4) 7 3 50 33 (PPV: 70; FDG: 24 <sup>18</sup> Flfuoro-2-deoxy-D-glucose; PET: positron emission tomography; FUO: fever of unknown origin; n.: percentage of patients with mo	Author	Design	N.	IF (%)	ID (%)	NP (%)	MISC (%)	ND (%)	PET helpful (%)	
Lorenzen et al. <sup>53</sup> r     16     19     50 (18)     6     6     19     69 (PPV: 92; Bleeker-Rovers et al. <sup>55</sup> r     35     17     11 (3)     17     9     46     37 (PPV: 87; IR)     87; IR)     87; IR)     9     16     16     36     16 (PPV: 92; IR)     17     9     46     37 (PPV: 87; IR)     17     9     46     36     16 (PPV: 80; IR)     16     19     51     26 (PPV:;;;;;;;;;	Aeller <i>et al.</i> <sup>52</sup>	р	20	40	25 (15)	10	15	10	55 (PPV: 92; NPV: 75)	
Bleeker-Rovers et al. <sup>55</sup> r     35     17     11 (3)     17     9     46     37 (PPV: 87; Kjaer et al. <sup>56</sup> )       Buysschaert et al. <sup>57</sup> p     19     26     16 (5)     6     16     36     16 (PPV: 30; R); Signal et al. <sup>57</sup> Buysschaert et al. <sup>57</sup> r     74     9     5 (4)     16     19     51     26 (PPV:; R); Signal et al. <sup>58</sup> Bleeker-Rovers et al. <sup>58</sup> p     70     17     23 (4)     7     3     50     33 (PPV: 70; R); Signal et al. <sup>57</sup> FDG: 24 <sup>18</sup> Flfluoro-2-deoxy-D-glucose; PET: positron emission tomography; FUO: fever of unknown origin; n.: percentage of patients with me	Blockmans et al.54	p	58	18	29 (14)	10	9	34	41 (PPV: -; NPV: -)	
Kjaer et al. <sup>56</sup> p     19     26     16 (5)     6     16     36     16 (PPV; 30; 30; 30; 30; 30; 30; 30; 30; 30; 30	orenzen et al.53	r	16	19	50 (18)	6	6	19	69 (PPV: 92; NPV: 100	
Buysschaert <i>et al.</i> <sup>57</sup> r 74 9 5 (4) 16 19 51 26 (PPV:; 1) Bleeker-Rovers <i>et al.</i> <sup>58</sup> p 70 17 23 (4) 7 3 50 33 (PPV; 70; 1) FDG: 24[ <sup>18</sup> F]fluoro-2-deoxy-D-glucose; PET: positron emission tomography; FUO: fever of unknown origin; n.: percentage of patients with me	Bleeker-Rovers et al.55	r	35	17	11 (3)	17	9	46	37 (PPV: 87; NPV: 95)	
Bleeker-Rovers <i>et al.</i> <sup>58</sup> p 70 17 23 (4) 7 3 50 33 (PPV; 70; 1 FDG: 2-[1 <sup>8</sup> F]fluoro-2-deoxy-D-glucose; PET: positron emission tomography; FUO: fever of unknown origin; n.: percentage of patients with me	jaer et al.56	р	19	26	16 (5)	6	16	36	16 (PPV: 30; NPV: 67)	
FDG: 2:[ <sup>18</sup> F]fluoro-2-deoxy-D-glucose; PET: positron emission tomography; FUO: fever of unknown origin; n.: percentage of patients with me	Buysschaert et al.57	r	74	9	5(4)	16	19	51	26 (PPV:; NPV:)	
	Bleeker-Rovers et al.58	р	70	17	23 (4)	7	3	50	33 (PPV: 70; NPV: 92)	
b: prospective, r: retrospective; PPV: positive prospective value; NPV: negative prospective value.	arge sized vasculitis in a study;	; IF: infection	; ID: inflar	mmatory non-	infectious disea	ase; NP: neopla	isia; MISC: miscel			





- Definition of FUO differs
- Patient recruitment: classic FUO or postoperative sepsis
- FDG-PET technique
- No standardized diagnostic protocol
- No final diagnosis in all patients




Predictors of helpful FDG-P Variable	FDG-PET helpful (N-19)	FDG-PET noncontributory (N-55)	Р
Male gender	10 (53)	30 (55)	0.9
Age, years	57 (38-73)	50 (30-66)	0.1
Episodic fever	5 (26)	25 (46)	0.1
Duration of illness, days	30 (21-140)	60 (22-120)	1.0
Maximum temperature, °G	39.0 (38.5-39.5)	39.2 (38.8-40.0)	0.2
Erythrocyte sedimentation rate, mm/h	78 (56-110)	52 (25-103)	0.1
C-reactive protein, mgA	67 (19-120)	77 (38-158)	0.6
Hemoglobin, gA	11.6 (10.0-12.0)	11.6 (10.4-13.5)	0.6

PET-scintigra	aphy i		ents with aminatio		who und	lerwent
		PET scar	1		Galliumse	an
Diagnostic category	normal	contributory	non- contributory	normal	contributory	non- contributory
infections $(n = 8)$	0	4	4	3	3	2
tumours $(n = 3)$	1	1	1	1	0	2 3
multi-system diseases (n = 12)	2	8	2	3	6	-
(vasculitis n = 4)	(0)	(4)	(0)	(2)	(2)	(0)
miscellaneous $(n = 3)$	2 4	1	0	1	1	1 9
no diagnosis (n = 14)		0	10	5	0	
total (n = 40)	9	14 (35 %)	17	13	10 (25 %)	17







### FDG PET(-CT) IMAGING IN FUO

- Advantages of FDG-PET
  - High resolution
  - Sensitivity in chronic low-grade infections
  - High accuracy in the central skeleton
  - Detection of vasculitis
- Theoretical disadvantage impossibility of differentiating between malignancy and infectious diseases or inflammation
- Disadvantages of FDG-PET
  - Relatively high cost
  - Limited availability
- Conclusion:
- FDG-PET is a valuable imaging technique as part of a structured diagnostic protocol in patients with FUO and raised CRP
- Very high negative predictive value


Bleeker-Rovers, EJNMI 2007; 34:694-703

### Total Body Inflammation/infection scan

- <sup>67</sup>Ga-scintigraphy
- Labeled leucocytes
- FDG PET
  - Summary
  - Examples

### FDG PET(-CT) IMAGING IN FUO


- 70-year-old female
- fever, fatigue and weight loss of 3 weeks' duration.
- A lymph node biopsy obtained by mediastinoscopy demonstrated granulomatous inflammation confirming a diagnosis of sarcoidosis. •
- Symptoms resolved upon treatment with corticosteroids




Bleeker-Rovers, EJNMI 2007; 34:694-703


### FDG PET(-CT) IMAGING IN FUO


- 76-year-old female •
- Fever and weight loss
- Blood, urine, broncho-alveolar lavage fluid and bone marrow cultures .
- were negative.
- •
- Chest X-ray, abdominal and thoracic CT scans, MRI of the spine, bone scan, lung perfusion scintigraphy, 111In-WBC scan, gastroscopy, colonoscopy and bronchoscopy were all normal. Duodenum, liver, bone and temporal artery biopsies were normal. .














### Therapeutic trials

- NSAID, cave Still's disease (hepatotoxicity
- If clinical deterioration (only than)
  - -AB's
    - Broad spectrum (re-assessment after 3-4 days, if no response, stop)
    - Tetracyclines?
  - Anti-TB
  - Corticosteroids (never without anti-TB), late



- « pdc » = potentially diagnostic clues
  - Look for them
- If no pdc's and/or directed examinations neg.
  - Staged approach
  - Total body inflammation/infection scan
  - Therapeutic trials
  - Wait and see strategy

### FUO in surviving undiagnosed cases (n=49)

- Spontaneous resolution (during/shortly post-hosp) n=31
- Persisting or recurring fever (>3 m post-discharge) n=18

– Cured :	n=10
– Unresolved :	n= 8
Treated with corticosteroids	n= 1
Treated with NSAID	n=6
Refused reinvestigation and died	n=1

Knockaert et al. Arch Int Med 1996; 156: 618

## Thank you for your attention